The Technical Analyst
Aldeyra Therapeutics Inc [ALDX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Aldeyra Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-3.02% $3.86
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 227.34 mill |
| EPS: | -0.640 |
| P/E: | -6.03 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 58.90 mill |
| Avg Daily Volume: | 0.593 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.03 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.03x |
| Company: PE -6.03 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.16 (-44.11%) $-1.703 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.64 - 4.06 ( +/- 5.51%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-12 | Machatha Stephen | Sell | 11 537 | Common Stock |
| 2024-03-11 | Greenberg Bruce | Sell | 13 201 | Common Stock |
| 2024-04-05 | Perceptive Advisors Llc | Buy | 37 712 | Common Stock |
| 2024-04-04 | Perceptive Advisors Llc | Buy | 140 281 | Common Stock |
| 2024-04-03 | Perceptive Advisors Llc | Buy | 309 847 | Common Stock |
| INSIDER POWER |
|---|
| 17.89 |
| Last 100 transactions |
| Buy: 8 132 048 | Sell: 3 580 213 |
Forecast:
16:00 - $3.86
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.86
Forecast 2: 16:00 - $3.86
Forecast 3: 16:00 - $3.86
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.86 (-3.02% ) |
| Volume | 0.423 mill |
| Avg. Vol. | 0.593 mill |
| % of Avg. Vol | 71.31 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALDX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | sell | $3.21 | N/A | Active |
|---|
ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Latest Press Releases
2024-04-18 07:00:00 - Press Release
Aldeyra Therapeutics To Host Research & Development Day On April 25, 2024
Lexington, mass.--(business wire)--aldeyra therapeutics, inc. (nasdaq: aldx) (aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a research & development day from 9:00a.m. to 1:00p.m. et on thursday, april 25, 2024 in new york city. aldeyra will provide an in-depth review of pipeline programs, and the event will feature presentations from members of the aldey.
2024-03-28 07:00:00 - Press Release
Aldeyra Therapeutics Announces Clinical Development Plan For Resubmission Of New Drug Application For Reproxalap In Dry Eye Disease
Lexington, mass.--(business wire)--aldeyra therapeutics, inc. (nasdaq: aldx) (aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable resubmission of a new drug application (nda) of topical ocular 0.25% reproxalap, an investigational rasp modulator, for the treatment of dry eye disease to the u.s. food and drug administration (fda). foll.
2024-02-06 07:00:00 - Press Release
Aldeyra Therapeutics To Participate In The Oppenheimer 34th Annual Healthcare Life Sciences Conference
Lexington, mass.--(business wire)--aldeyra therapeutics, inc. (nasdaq: aldx) (aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that todd c. brady, m.d., ph.d., president and chief executive officer, will participate in a fireside chat at the oppenheimer 34th annual healthcare life sciences conference. the conference will be held virtually on february 13-14, 2024. dr. brady's conversation with justin k.
2023-12-19 07:00:00 - Press Release
Aldeyra Therapeutics Announces Statistically And Clinically Significant Improvement From Baseline In Phase 2 Clinical Trial Of Adx‑629 In Patients With Atopic Dermatitis
Lexington, mass.--(business wire)--aldeyra therapeutics, inc. (nasdaq: aldx) (aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced positive top-line results from a phase 2 clinical trial of adx-629, an investigational rasp modulator, in patients with atopic dermatitis. relative to baseline, the clinical trial demonstrated statistically significant and clinically relevant improvement in investigat.
2023-12-18 16:01:00 - Press Release
Aldeyra Therapeutics Schedules Conference Call And Webcast To Announce Top-line Results From Phase 2 Clinical Trial Of Adx-629 In Patients With Atopic Dermatitis
Lexington, mass.--(business wire)--aldeyra therapeutics, inc. (nasdaq: aldx) (aldeyra) today announced it will host a webcast and conference call on tuesday, december 19, 2023, at 8:00 a.m. (et) to provide top-line results from a phase 2 clinical trial of adx‑629 in patients with atopic dermatitis. the dial-in numbers are (888) 415-4305 for domestic callers and (646) 960-0336 for international callers. the access code is 5858366. a live audio webcast of the conference call also will be accessib.
Latest News
2024-04-07 08:55:46 - 24/7 Wall Street
Insiders Scoop Up Shares of These 5 Stocks for the Second Quarter
Although the number and size of insider purchases have been somewhat lower as the second quarter begins, the following beneficial owners and other insiders were still showing their love for these five stocks.
2024-04-06 07:41:03 - Zacks Investment Research
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.
2024-03-24 00:46:24 - Seeking Alpha
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tiered double-digit royalties for ex-US. $142M in cash at 12/31/23, burning $40M per year - plenty of cash to achieve monetization of reproxalap.
2024-03-06 10:41:16 - Zacks Investment Research
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.
2024-02-29 09:56:09 - Zacks Investment Research
5 Small Drug Stocks to Buy From a Rebounding Industry
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
2024-01-28 02:56:00 - Seeking Alpha
Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects
Aldeyra Therapeutics is a biotech company focused on developing treatments for immune-mediated inflammatory diseases, with its leading drug candidate being Reproxalap for dry eye and allergic conjunctivitis. The company has an option agreement with AbbVie, indicating strategic M&A value and potential for a takeover. ALDX's current market cap of $181.76 million is mostly its cash value of $144.33 million, making it a strong buy with significant upside potential.
2023-12-18 16:01:00 - Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to provide top-line results from a Phase 2 clinical trial of ADX‑629 in patients with atopic dermatitis. The dial-in numbers are (888) 415-4305 for domestic callers and (646) 960-0336 for international callers. The access code is 5858366. A live audio webcast of the conference call also will be accessib.
2023-12-05 10:32:11 - Zacks Investment Research
Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings?
Aldeyra Therapeutics (ALDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2023-12-01 13:32:23 - Zacks Investment Research
BOX Gears Up to Report Q3 Earnings: What's in the Offing?
BOX's fiscal third-quarter results are likely to reflect strength in content cloud solutions.
2023-11-07 14:12:53 - PennyStocks
Invest In Penny Stocks? Is It Worth It & 4 To Watch Now
If you're looking for penny stocks to invest in right now, you've got your work cut out for you. That's because the initial strategy when approaching cheap stocks is to trade them in the short term instead of holding them forever.